|
GB1351025A
(en)
*
|
1971-08-20 |
1974-04-24 |
Aron Md Samuel J |
Oxadiazol-5-yl biguanide derivatives method for their preparation and pharmaceutical compositions containing them
|
|
ZA876930B
(en)
|
1986-10-07 |
1988-05-25 |
Hoffmann La Roche |
Pharmaceutical compositions
|
|
IT1245890B
(it)
|
1991-04-12 |
1994-10-25 |
Alfa Wassermann Spa |
Formulazioni farmaceutiche per uso orale gastroresistenti contenenti acidi biliari.
|
|
GB9203347D0
(en)
|
1992-02-17 |
1992-04-01 |
Wellcome Found |
Hypolipidaemic compounds
|
|
US5234697A
(en)
|
1992-06-22 |
1993-08-10 |
Digestive Care Inc. |
Compositions of gastric acid-resistant microspheres containing salts of bile acids
|
|
US5415872A
(en)
|
1992-06-22 |
1995-05-16 |
Digestive Care Inc. |
Compositions of gastric acid-resistant microspheres containing salts of bile acids
|
|
IL108633A
(en)
|
1993-02-15 |
1998-07-15 |
Wellcome Found |
History of Benzothiazepine Hypolipidemic Preparation and Pharmaceutical Preparations Containing Them
|
|
IL108634A0
(en)
|
1993-02-15 |
1994-05-30 |
Wellcome Found |
Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
|
|
KR970005178B1
(ko)
|
1993-12-28 |
1997-04-14 |
이승철 |
피로회복제 조성물
|
|
US5589358A
(en)
|
1993-12-29 |
1996-12-31 |
Univ Wake Forest |
Ileal bile acid transporter compositions and methods
|
|
ZA956647B
(en)
|
1994-08-10 |
1997-02-10 |
Wellcome Found |
Hypolipidaemic compounds.
|
|
US6268392B1
(en)
|
1994-09-13 |
2001-07-31 |
G. D. Searle & Co. |
Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
|
|
US6107494A
(en)
|
1994-09-13 |
2000-08-22 |
G.D. Searle And Company |
Substituted 5-aryl-benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
|
US6642268B2
(en)
|
1994-09-13 |
2003-11-04 |
G.D. Searle & Co. |
Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
|
|
US6262277B1
(en)
|
1994-09-13 |
2001-07-17 |
G.D. Searle And Company |
Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
|
US5994391A
(en)
*
|
1994-09-13 |
1999-11-30 |
G.D. Searle And Company |
Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
|
|
GB9423172D0
(en)
|
1994-11-17 |
1995-01-04 |
Wellcom Foundation The Limited |
Hypolipidemic benzothiazepines
|
|
US6861053B1
(en)
|
1999-08-11 |
2005-03-01 |
Cedars-Sinai Medical Center |
Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
|
|
DE04010088T1
(de)
|
1996-03-11 |
2005-07-14 |
G.D. Searle Llc |
Neue Benzothiepine mit pharmazeutischer Wirkung.
|
|
DE122010000020I1
(de)
|
1996-04-25 |
2010-07-08 |
Prosidion Ltd |
Verfahren zur Senkung des Blutglukosespiegels in Säugern
|
|
US5908830A
(en)
|
1996-10-31 |
1999-06-01 |
Merck & Co., Inc. |
Combination therapy for the treatment of diabetes and obesity
|
|
GB9704208D0
(en)
|
1997-02-28 |
1997-04-16 |
Glaxo Group Ltd |
Chemical compounds
|
|
ATE242258T1
(de)
|
1997-03-14 |
2003-06-15 |
Aventis Pharma Gmbh |
Hypolipidemische 1,4-benzothiazepin-1,1-dioxide
|
|
US5900233A
(en)
|
1997-10-16 |
1999-05-04 |
Day; Charles E. |
Epichlorohydrin and 1-(3-aminopropyl) imidazole copolymer and its use in treating irritable bowel syndrome
|
|
BR9814300A
(pt)
*
|
1997-12-19 |
2002-02-05 |
Searle & Co |
Método de preparação de óxidos de tetraidrobenzotiepina enanciomericamente enriquecidos
|
|
GB9800428D0
(en)
|
1998-01-10 |
1998-03-04 |
Glaxo Group Ltd |
Chemical compounds
|
|
EP1052994A2
(en)
|
1998-02-02 |
2000-11-22 |
Trustees Of Tufts College |
Use of dipeptidylpetidase inhibitors to regulate glucose metabolism
|
|
JP2000026300A
(ja)
|
1998-07-02 |
2000-01-25 |
Pola Chem Ind Inc |
血管内皮細胞保護医薬組成物
|
|
BR9916486A
(pt)
|
1998-12-23 |
2002-02-05 |
Searle Llc |
Combinações de inibidores do transporte de ácidos biliares no ìleo e inibidores da proteìna de transferência do ester colesteril para indicações cardiovasculares
|
|
SE9901387D0
(sv)
*
|
1999-04-19 |
1999-04-19 |
Astra Ab |
New pharmaceutical foromaulations
|
|
US6309663B1
(en)
|
1999-08-17 |
2001-10-30 |
Lipocine Inc. |
Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
|
|
TR200002099A2
(tr)
|
1999-07-22 |
2001-06-21 |
Sankyo Company Limited |
Siklobüten türevleri, bunların hazırlanması ve terapötik kullanımları
|
|
ATE385421T1
(de)
|
2000-01-21 |
2008-02-15 |
Novartis Pharma Gmbh |
Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica
|
|
SE0000772D0
(sv)
|
2000-03-08 |
2000-03-08 |
Astrazeneca Ab |
Chemical compounds
|
|
AU2001246905A1
(en)
|
2000-04-12 |
2001-10-23 |
Takeda Chemical Industries Ltd. |
Novel g protein-coupled receptor protein and dna thereof
|
|
US20020183307A1
(en)
*
|
2000-07-26 |
2002-12-05 |
Tremont Samuel J. |
Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake
|
|
KR100572785B1
(ko)
|
2000-07-28 |
2006-04-19 |
에프. 호프만-라 로슈 아게 |
신규한 약학 조성물
|
|
EP1749539A2
(en)
*
|
2000-08-01 |
2007-02-07 |
Shionogi Co., Ltd. |
Preventives or remedies for fatty liver
|
|
AU2001296033A1
(en)
|
2000-11-17 |
2002-05-27 |
Banyu Pharmaceutical Co. Ltd. |
Novel guanosine triphosphate (gtp) binding protein-coupled receptor protein, bg37
|
|
EG26979A
(en)
|
2000-12-21 |
2015-03-01 |
Astrazeneca Ab |
Chemical compounds
|
|
WO2002053548A1
(fr)
*
|
2000-12-27 |
2002-07-11 |
Banyu Pharmaceutical Co.,Ltd. |
Derives de la benzothiazepine
|
|
WO2002078625A2
(en)
|
2001-03-28 |
2002-10-10 |
Pharmacia Corporation |
Therapeutic combinations for cardiovascular and inflammatory indications
|
|
OA12983A
(en)
|
2001-07-19 |
2006-10-13 |
Pharmacia Corp |
Combination of an aldosterone receptor antagonist and an HMG COA reductase inhibitor.
|
|
WO2003018024A1
(de)
|
2001-08-22 |
2003-03-06 |
Aventis Pharma Deutschland Gmbh |
Kombinationspräparate von 1,4- benzothiepin-1,1-dioxidderivaten mit weiteren wirkstoffen und deren verwendung
|
|
GB0121337D0
(en)
|
2001-09-04 |
2001-10-24 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0121622D0
(en)
|
2001-09-07 |
2001-10-31 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0121621D0
(en)
|
2001-09-07 |
2001-10-31 |
Astrazeneca Ab |
Chemical compounds
|
|
MY131995A
(en)
|
2001-09-08 |
2007-09-28 |
Astrazeneca Ab |
Benzothiazepine and benzothiadiazepine derivatives with illeal bile acid transport (ibat) inhibitory activity for the treatment hyperlipidaemia
|
|
CA2462455C
(en)
|
2001-10-01 |
2012-07-17 |
The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Development of a preventive vaccine for filovirus infection in primates
|
|
BR0213501A
(pt)
|
2001-11-02 |
2004-08-24 |
Searle Llc |
Compostos de benzotiepina mono- e di-fluorada como inibidores de transporte de ácido biliar co-dependente de sódio apical (asbt) e captação de taurocolato
|
|
GB0229931D0
(en)
*
|
2002-12-21 |
2003-01-29 |
Astrazeneca Ab |
Therapeutic agents
|
|
MXPA04006255A
(es)
|
2002-01-17 |
2004-09-27 |
Pharmacia Corp |
Compuestos novedosos de alquil/aril hidroxi o ceto tiepina como inhibidores del transporte del acido biliar codependiente del sodio apical y la captacion de taurocolato.
|
|
GB0201850D0
(en)
|
2002-01-26 |
2002-03-13 |
Astrazeneca Ab |
Therapeutic treatment
|
|
US20040014806A1
(en)
|
2002-03-08 |
2004-01-22 |
Pharmacia Corporation |
Methods and compositions for lowering levels of blood lipids
|
|
GB0209467D0
(en)
|
2002-04-25 |
2002-06-05 |
Astrazeneca Ab |
Chemical compounds
|
|
CA2486909A1
(en)
|
2002-05-23 |
2003-12-04 |
Umd, Inc. |
Compositions and method for transmucosal drug delivery and cryoprotection
|
|
WO2004020421A1
(ja)
|
2002-08-28 |
2004-03-11 |
Asahi Kasei Pharma Corporation |
新規な４級アンモニウム化合物
|
|
US7312208B2
(en)
*
|
2002-08-28 |
2007-12-25 |
Asahi Kasei Pharma Corporation |
Quaternary ammonium compounds
|
|
US20040122033A1
(en)
|
2002-12-10 |
2004-06-24 |
Nargund Ravi P. |
Combination therapy for the treatment of obesity
|
|
US20040138145A1
(en)
|
2002-12-12 |
2004-07-15 |
Aventis Pharma S.A. |
Application of intestinal biliary acid reuptake inhibitors for the prevention and treatment of alzheimer's disease
|
|
GB0304194D0
(en)
|
2003-02-25 |
2003-03-26 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0307918D0
(en)
|
2003-04-05 |
2003-05-14 |
Astrazeneca Ab |
Therapeutic use
|
|
US20070099884A1
(en)
*
|
2003-06-06 |
2007-05-03 |
Erondu Ngozi E |
Combination therapy for the treatment of diabetes
|
|
JP2005097216A
(ja)
|
2003-09-26 |
2005-04-14 |
Kaneka Corp |
ＰＰＡＲγリガンド剤
|
|
AU2005217318B2
(en)
|
2004-02-27 |
2010-07-01 |
Asahi Kasei Pharma Corporation |
Novel benzothiazepine and benzothiepine compounds
|
|
AU2005284798B2
(en)
|
2004-09-15 |
2012-02-02 |
The President And Fellows Of Harvard College |
Reducing ER stress in the treatment of obesity and diabetes
|
|
JPWO2006041150A1
(ja)
*
|
2004-10-15 |
2008-05-22 |
田辺三菱製薬株式会社 |
糖尿病の予防および／または治療薬
|
|
EP1807066A1
(en)
*
|
2004-10-25 |
2007-07-18 |
Novartis AG |
Combination of dpp-iv inhibitor, ppar antidiabetic and metformin
|
|
EP1819318A1
(en)
|
2004-11-24 |
2007-08-22 |
Seo Hong Yoo |
Dried forms of aqueous solubilized bile acid dosage formulation
|
|
US20070032420A1
(en)
|
2005-02-09 |
2007-02-08 |
Entelos, Inc. |
Treating diabetes with glucagon-like peptide-1 secretagogues
|
|
US20060193895A1
(en)
|
2005-02-25 |
2006-08-31 |
Use-Techno Corporation |
Additive for food and beverage, pharmaceutical composition, GLUT4 translocator, and method for translocating GLUT4
|
|
FR2883284A1
(fr)
|
2005-03-15 |
2006-09-22 |
Commissariat Energie Atomique |
Nouveaux derives dihydropyrimidines et leur utilisation comme agents anti-cancereux
|
|
US20060222709A1
(en)
*
|
2005-03-18 |
2006-10-05 |
Agi Therapeutics Research Ltd. |
Metformin methods and formulations for treating chronic constipation
|
|
UY29445A1
(es)
*
|
2005-03-30 |
2006-10-02 |
Generex Pharm Inc |
Composiciones para la transmisión transmucosa oral de la metformina
|
|
US20080031968A1
(en)
|
2005-04-01 |
2008-02-07 |
The Brigham And Women's Hospital, Inc. |
Methods for increasing cellular energy expenditure
|
|
AU2006231071B2
(en)
|
2005-04-04 |
2012-09-06 |
Julius-Maximilians-Universitaet Wuerzburg |
Tripeptides that down regulate the activity of plasma membrane transporters including sodium-D-glucose cotransporter SGLT1
|
|
EP1874330A2
(en)
|
2005-04-04 |
2008-01-09 |
Julius-Maximilians-Universität Würzburg |
Peptides that down regulate the activity of plasma membrane transporters including sodium-d-glucose cotransporter sglt1
|
|
WO2006116814A1
(en)
|
2005-05-02 |
2006-11-09 |
Vanadis Bioscience Ltd |
Composition and uses thereof
|
|
US20070025953A1
(en)
|
2005-07-27 |
2007-02-01 |
Jones Michael R |
Co-therapy for diabetic conditions
|
|
EP1940388A2
(en)
|
2005-09-30 |
2008-07-09 |
Novartis AG |
Dpp iv inhibtor for use in the treatment of autoimmune diseases and graft rejection
|
|
ATE526318T1
(de)
|
2005-12-19 |
2011-10-15 |
Glaxosmithkline Llc |
Farnesoid-x-rezeptor-agonisten
|
|
CN101404987A
(zh)
|
2006-01-20 |
2009-04-08 |
史密丝克莱恩比彻姆公司 |
磺酰胺衍生物在治疗代射和神经系统疾病中的用途
|
|
CN101395170A
(zh)
|
2006-02-14 |
2009-03-25 |
英特塞普特药品公司 |
用于预防或治疗fxr介导的疾病或状态的作为fxr配体的胆汁酸衍生物
|
|
DK2040713T3
(da)
|
2006-06-27 |
2014-09-29 |
Intercept Pharmaceuticals Inc |
Galdesyrederivater som fxr-ligander til forebyggelsen eller behandlingen af fxr-medierede sygdomme eller tilstande
|
|
WO2008028037A2
(en)
|
2006-08-30 |
2008-03-06 |
Andrew Young |
Distender device and method for treatment of obesity and metabolic and other diseases
|
|
CL2007003035A1
(es)
|
2006-10-24 |
2008-05-16 |
Smithkline Beechman Corp |
Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos,
|
|
ATE493992T1
(de)
|
2006-11-14 |
2011-01-15 |
Sanofi Aventis Deutschland |
Neue 1,4-benzothiepin-1,1-dioxidderivate mit verbesserten eigenschaften, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
DE102006053635B4
(de)
|
2006-11-14 |
2011-06-30 |
Sanofi-Aventis Deutschland GmbH, 65929 |
Neue mit Benzylresten substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
|
US20090035306A1
(en)
|
2006-11-29 |
2009-02-05 |
Kalypsys, Inc. |
Quinazolinone modulators of tgr5
|
|
CA2928178C
(en)
|
2007-01-19 |
2019-09-10 |
Intercept Pharmaceuticals, Inc. |
Tgr5 modulators and methods of use thereof
|
|
US20080221161A1
(en)
|
2007-02-09 |
2008-09-11 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5 for treatment of disease
|
|
AU2008288770B2
(en)
|
2007-08-23 |
2014-06-12 |
Theracosbio, Llc |
Benzylbenzene derivatives and methods of use
|
|
HUE039171T2
(hu)
|
2008-11-19 |
2018-12-28 |
Intercept Pharmaceuticals Inc |
TGR5 modulátorok és azok alkalmazási eljárása
|
|
US8318663B2
(en)
|
2008-11-26 |
2012-11-27 |
Satiogen Pharmaceuticals, Inc. |
Methods of treating diabetes and/or obesity using an enteroendocrine peptide secretion enhancing agent
|
|
EP2367554A4
(en)
|
2008-11-26 |
2020-03-25 |
Satiogen Pharmaceuticals, Inc. |
Bile acid reflux inhibitor for the treatment of obesity and diabetes
|
|
US20110065676A1
(en)
|
2009-06-24 |
2011-03-17 |
Schering Corporation |
Combination therapies comprising par1 antagonists with nar agonists
|
|
EP4137137A1
(en)
|
2010-05-26 |
2023-02-22 |
Satiogen Pharmaceuticals, Inc. |
Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
|
|
MX366925B
(es)
|
2010-11-04 |
2019-07-31 |
Albireo Ab |
Inhibidores de ibat para el tratamiento de enfermedades hepaticas.
|
|
MY176863A
(en)
|
2010-11-08 |
2020-08-24 |
Albireo Ab |
Ibat inhibitors for treatment of metabolic disorders and related conditions
|
|
US20130236541A1
(en)
|
2010-11-08 |
2013-09-12 |
Albireo Ab |
Pharmaceutical combination comprising an ibat inhibitor and a bile acid binder
|